Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study
• People who are 18 years of age or older at the time of signing the consent form
• People who are willing and able to stay in hospital as required after receiving the study treatment, and to follow all study procedures
• People who have been diagnosed with a specific type of blood cancer called diffuse large B-cell lymphoma (DLBCL), or a closely related type, confirmed through a tissue test — this includes DLBCL-NOS, HGBCL, PMBCL, or follicular lymphoma that has transformed into DLBCL
• People whose lymphoma has come back or stopped responding to treatment after at least two previous rounds of treatment, including at least one treatment containing a drug called an anthracycline and at least one treatment targeting a protein called CD20
• People who have at least one area of measurable disease visible on scans (a swollen lymph node larger than 1.5 cm, or a growth outside the lymph nodes larger than 1.0 cm)
• People who can provide a tissue sample from their cancer, or where the trial site doctor confirms this is not possible
• People with a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
• People with a life expectancy of at least 12 weeks, as assessed by the trial doctor
• People whose side effects from previous cancer treatments have largely resolved to a mild level (except for hair loss or reduced appetite)
• People with adequate liver function, based on blood test results falling within specified ranges
• People with adequate blood cell counts, based on blood test results falling within specified ranges, with no recent blood or platelet transfusions in the days before the first treatment
• People with adequate kidney function, based on blood test results or a kidney function calculation falling within specified ranges
• Women who could become pregnant must have a negative pregnancy test within 7 days before starting treatment, and must agree to use contraception or avoid heterosexual intercourse during the study
• Men must agree to use contraception or avoid heterosexual intercourse during the study

Who may not be able to join:

• People who are unable or unwilling to comply with the required hospital stays and study restrictions
• People whose DLBCL has developed from a condition called chronic lymphocytic leukaemia (known as Richter's transformation)
• People with an active bacterial, viral, fungal, or other infection at the time of joining, or who have had a major infection within 4 weeks before the first study treatment
• People with suspected or confirmed latent tuberculosis, identified through a specific blood test
• People with an active hepatitis B virus infection (confirmed by a positive surface antigen blood test); people with a past or hidden hepatitis B infection may be considered if certain conditions are met (confirm with trial site)
• People with a positive hepatitis C antibody test, unless a further test confirms the virus is no longer active in the blood
• People known to be HIV positive; people with unknown HIV status may be tested if required by local regulations
• People with a known or suspected ongoing Epstein-Barr virus infection
• People with a known or suspected history of a rare immune condition called haemophagocytic lymphohistiocytosis (HLH)
• People who are pregnant, breastfeeding, or planning to become pregnant during treatment or within a specified period after the last dose
• People who have previously had serious immune-related side effects from certain cancer treatments, including severe reactions or milder reactions that did not fully resolve after stopping treatment
• People whose lymphoma has been shown not to respond to a specific medication called obinutuzumab
• People with an active autoimmune disease that currently requires treatment
• People with other serious uncontrolled health conditions that could interfere with the study, including significant lung problems or autoimmune diabetes
• People with a history of severe allergic reactions to antibody-based treatments
• People with a confirmed history of a serious brain condition called progressive multifocal leukoencephalopathy (PML)
• People with a current or past history of lymphoma affecting the brain or spinal cord
• People with a current or past history of certain brain or nervous system conditions, such as stroke, epilepsy, inflammation of blood vessels in the brain, or a degenerative neurological disease
• People who have had another active invasive cancer within the last 2 years (with some exceptions for certain low-risk skin cancers — confirm with trial site)
• People with serious heart conditions, including severe heart failure, a heart attack within the last 6 months, unstable heart rhythm, or significant coronary artery disease
• People who have received a live vaccine within 4 weeks before starting the study treatment, or who are expected to need one during the study
• People who have received certain immune-suppressing or chemotherapy medications within 2 weeks before starting study treatment (low-dose steroids, inhaled steroids, and topical steroids are generally permitted — confirm with trial site)
• People with a history of illicit drug use or alcohol misuse within the 12 months before screening
• People with any other medical condition, abnormal test result, or health concern that the trial doctor believes makes participation unsafe
• People with a mental health condition or cognitive difficulty that would prevent them from understanding and following the study requirements
• People in any other situation that the trial doctor considers makes them unsuitable for the trial

Important: Always verify eligibility with the trial site directly before applying.